Home Biosimilar Antibodies Transmembrane Transporters CD markers Gemtuzumab (Anti-Siglec-3 / CD33)
For research use only. Not for use in humans.

Gemtuzumab (Anti-Siglec-3 / CD33)

Synonyms: Cd33,Siglec-3

Gemtuzumab (Anti-Siglec-3 / CD33) a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). It can be used for the research of acute myeloid leukemia.MW :145.22 KD.

Gemtuzumab (Anti-Siglec-3 / CD33)

Quality Control

Batch: Purity: 99% Protein concentration: 9.216mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Gemtuzumab (Anti-Siglec-3 / CD33) a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). It can be used for the research of acute myeloid leukemia.MW :145.22 KD.
References

Product Details

Isotype Human IgG4SP
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07026942 NOT_YET_RECRUITING Relapsed/Refractory AML Nationwide Children's Hospital 2026-04-01 PHASE1; PHASE2
NCT02724163 ACTIVE_NOT_RECRUITING Drug: Gemtuzumab ozogamicin|Drug: Liposomal daunorubicin|Dru Acute Myeloid Leukaemia University of Birmingham 2016-04 PHASE3
NCT05904106 RECRUITING Drug: Venetoclax plus Azacitidine|Drug: standard of care che Acute Myeloid Leukemia Technische Universität Dresden 2024-04-07 PHASE2
NCT07676006 NOT_YET_RECRUITING Relapsed/Refractory Acute Myeloid Leukemia (AML) Grit Biotechnology 2026-07-01 EARLY_PHASE1
NCT05995041 NOT_YET_RECRUITING Acute Myeloid Leukemia Shenzhen Geno-Immune Medical Institute 2027-06-30 PHASE1
NCT03971799 ACTIVE_NOT_RECRUITING Acute Myelogenous Leukemia Center for International Blood and Marrow Transplant Research 2020-01-08 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-11-12)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.